prostat
cancer
second
frequent
diagnos
cancer
sixth
deadli
cancer
male
worldwid
usa
prostat
cancer
commonli
diagnos
cancer
male
age
year
rank
second
deadliest
cancer
male
tradit
treatment
prostat
cancer
includ
prostectomi
radiat
therapi
chemotherapi
hormon
depriv
therapi
treatment
impair
qualiti
life
patient
thu
new
approach
combat
prostat
cancer
warrant
sever
group
explor
method
har
immun
system
recogn
kill
prostat
cancer
cell
one
effort
led
sipuleucelt
licens
autolog
cellular
immunotherapi
treatment
asymptomat
minim
symptomat
metastat
castrateresist
prostat
cancer
addit
immunotherapi
prostat
cancer
develop
includ
number
vaccin
candid
well
approach
use
target
monoclon
antibodi
mab
prostatespecif
membran
antigen
psma
express
mani
fold
higher
prostat
cell
cell
tissu
consid
import
clinic
biomark
prostat
cancer
level
psma
elev
prostat
cancer
cell
studi
indic
strong
correl
increas
psma
express
prostat
cancer
progress
psma
express
level
also
elev
malign
cell
includ
urolog
origin
ie
kidney
bladder
suggest
glycoprotein
may
play
role
oncogen
progress
well
solid
tumor
includ
colon
ovarian
breast
kidney
cancer
elev
psma
express
observ
tumor
neovasculatur
normal
vasculatur
suggest
role
psma
angiogenesi
unlik
prostatespecif
antigen
psa
pmsa
membran
protein
make
attract
target
develop
mab
diagnost
therapeut
purpos
sever
therapeut
antipsma
mab
develop
mani
use
radioimmunotherapi
target
cytotox
radionucleotid
specif
psmaexpress
cell
antipsma
mab
clone
demonstr
mediat
therapeut
effect
promot
antibodydepend
cellular
cytotox
adcc
effect
kill
prostat
cancer
cell
dna
plasmid
use
year
nonvir
method
vivo
gene
deliveri
studi
extens
platform
vaccin
gene
therapi
recent
group
explor
develop
synthet
dna
plasmid
mean
deliv
gene
mab
neutral
infecti
agent
report
construct
express
dnaencod
monoclon
antibodi
dmab
direct
vivo
product
function
level
antibodi
target
human
immunodefici
dengu
chikungunya
virus
mice
approach
possess
sever
advantag
convent
proteinbas
mab
viral
vectorbas
deliveri
antibodi
gene
includ
lower
product
cost
abil
gener
durabl
high
level
vivo
antibodi
product
without
gene
integr
abil
repeat
administr
due
nonimmunogen
natur
dna
plasmid
earli
applic
dna
plasmid
technolog
suffer
due
poor
vivo
transgen
product
recent
enhanc
design
dna
vector
along
new
deliveri
method
includ
adapt
vivo
electropor
ep
combin
boost
transgen
express
potent
level
clinic
vaccin
studi
without
compromis
safeti
studi
describ
first
applic
enhanc
synthet
dna
plasmid
technolog
deliv
dna
direct
vivo
product
human
mab
cancer
immunotherapi
design
novel
construct
encod
therapeut
antipsma
mab
show
plasmid
express
dmab
vitro
vivo
mice
epenhanc
intramuscular
deliveri
vivo
gener
antibodi
retain
abil
bind
specif
psma
possess
adcc
activ
final
show
antipsmadmab
control
growth
psmaposit
tumor
mous
model
like
engag
nk
cell
cell
line
use
studi
purchas
american
type
cultur
collect
atcc
atcc
transgen
adenocarcinoma
mous
prostat
tramp
atcc
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibcolif
technolog
supplement
fb
penicillinstreptomycin
lymph
node
carcinoma
prostat
lncap
clone
fgc
atcc
cell
maintain
gibcolif
technolog
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
commerci
antipsma
control
mab
obtain
r
system
construct
psmadmab
gene
variabl
heavi
v
h
variabl
light
v
l
fragment
human
antipsma
mab
examin
optim
construct
use
synthet
oligonucleotid
sever
modif
improv
express
previous
describ
dna
formul
water
subsequ
administr
mice
empti
express
vector
use
neg
control
cell
transfect
psmadmab
plasmid
confirm
psmadmab
bind
recombin
human
psma
carri
western
blot
analysi
briefli
recombin
psma
protein
r
system
run
sdspage
gel
transfer
immobilonpvdf
membran
emd
millipor
membran
block
h
block
buffer
licor
bioscienc
incub
h
either
commerci
antipsma
mab
r
system
pool
day
sera
psmadmab
plasmidinject
mice
supernat
psmadmab
plasmidtransfect
cell
membran
wash
incub
h
goat
antihuman
igg
antibodi
licor
bioscienc
wash
protein
band
visual
scan
membran
licor
odyssey
clx
scanner
anim
experi
conduct
accord
univers
pennsylvania
anim
care
use
committe
guidelin
nu
j
nude
jackson
laboratori
mice
administ
psmadmab
plasmid
singl
intramuscular
inject
quadricep
follow
vivo
electropor
quantifi
human
immunoglobulin
level
elisa
plate
coat
goat
antihuman
iggfc
fragment
antibodi
bethyl
overnight
follow
day
plate
wash
phosphatebuff
salin
pbst
block
fb
pbst
h
room
temperatur
wash
incub
h
room
temperatur
respect
sampl
dilut
fb
pbst
wash
incub
h
room
temperatur
hrpconjug
goat
antihuman
kappa
light
chain
antibodi
bethyl
sigmafast
opd
sigmaaldrich
solut
ad
well
plate
kept
dark
least
min
color
develop
enzymat
reaction
stop
n
h
plate
read
nm
standard
curv
gener
use
purifi
human
iggkappa
bethyl
bind
elisa
evalu
antibodi
affin
follow
similar
procedur
except
plate
coat
overnight
recombin
human
psma
hrpconjug
goat
antihuman
igg
h
l
bethyl
use
secondari
antibodi
detect
cell
surfac
psma
tube
lncap
cell
wash
phosphatebuff
salin
pb
stain
livedead
fixabl
violet
dead
cell
stain
life
technolog
min
wash
twice
fac
buffer
pb
fb
cell
next
incub
min
room
temperatur
dilut
day
sera
psmadmab
plasmidinject
mice
wash
final
cell
incub
dark
min
dilut
peconjug
antihuman
fc
igg
biolegend
follow
final
wash
fac
buffer
sampl
resuspend
stabil
fix
bd
analyz
follow
day
flow
cytomet
bd
bioscienc
fac
analysi
perform
gate
low
forward
scatter
side
scatter
annexinv
fitc
pi
thermo
fisher
follow
kit
protocol
effect
psmadmab
sera
lncap
cell
death
formalinfix
paraffinembed
ffpe
human
tumor
tissu
section
umass
cancer
center
tissu
tumor
bank
massachusett
deparaffin
xylen
rehydr
antigen
retriev
perform
use
work
solut
citrat
buffer
ph
sigmaaldrich
min
tissu
section
block
pb
contain
normal
goat
serum
cell
signal
technolog
triton
humid
chamber
tissu
wash
pb
incub
pool
day
psmadmab
plasmidadminist
mice
sera
dilut
antibodi
diluent
tissu
wash
pb
incub
dilut
alexa
fluor
goat
antihuman
igg
h
l
secondari
antibodi
thermo
fisher
scientif
antibodi
diluent
h
cell
nuclei
counterstain
hoechst
reagent
sigmaaldrich
imag
acquir
use
leica
tc
confoc
laser
scan
microscop
cell
development
biolog
microscopi
core
univers
pennsylvania
pa
usa
paraffinembed
mous
prostat
tissu
subject
antigen
retriev
deparaffin
slide
fix
aceton
wash
pb
section
block
use
normal
goat
serum
follow
stain
human
psma
antibodi
follow
biotinyl
goat
antimous
complet
immunohistochem
procedur
accord
manufactur
instruct
vector
lab
adcc
activ
psmadmab
examin
use
promega
adcc
report
bioassay
kit
briefli
target
lncap
cell
incub
h
engin
jurkat
effector
cell
pool
day
sera
psmadmab
plasmidinject
mice
luciferas
activ
measur
luminesc
determin
adcc
activ
recommend
manufactur
sera
sampl
test
triplic
tumor
implant
male
mice
inject
subcutan
cell
right
hind
flank
experiment
mice
divid
treatment
group
anim
monitor
tumor
growth
tumor
becam
detect
electron
calip
use
measur
length
width
tumor
tumor
volum
calcul
appli
follow
equat
univers
pennsylvania
anim
care
use
committe
guidelin
mice
sacrif
tumor
diamet
reach
cm
tumor
becam
ulcer
surviv
differ
group
analyz
student
test
p
consid
signific
mice
treat
nk
cell
deplet
day
tumor
challeng
day
tumor
inocul
intraven
inject
either
control
igg
antiasialo
igg
wako
chemic
richmond
va
usa
dilut
pb
cell
stain
monoclon
antibodi
analyz
flow
cytometri
verifi
deplet
nk
cell
popul
antiasialo
anim
graphpad
prism
graphpad
softwar
inc
program
use
statist
analysi
data
data
elisa
assay
express
mean
sd
repres
least
three
differ
experi
comparison
individu
data
point
made
use
student
test
p
valu
consid
statist
signific
human
psma
type
ii
integr
membran
glycoprotein
highli
express
prostat
secretoryacinar
epithelium
well
sever
extraprostat
tissu
possess
ident
similar
mous
psma
plasmid
capabl
direct
vivo
antibodi
product
design
creat
cassett
consist
fulllength
code
sequenc
variabl
heavi
v
h
light
v
l
immunoglobulin
ig
chain
publish
sequenc
antipsma
mab
driven
cmv
promot
optim
cassett
sequenc
improv
express
clone
cassett
fig
antibodi
target
psma
produc
optim
dna
plasmid
henceforth
refer
psmadmab
confirm
plasmid
direct
product
fulli
assembl
igg
human
embryon
kidney
cell
transfect
either
empti
psmadmab
plasmid
supernat
collect
cell
h
posttransfect
assay
elisa
quantifi
total
human
igg
level
concentr
nearli
ngml
human
igg
measur
supernat
psmadmab
plasmidtransfect
cell
fig
bind
elisa
perform
supernat
indic
igg
produc
psmadmab
plasmidtransfect
cell
bound
recombin
human
psma
high
affin
fig
western
blot
analysi
confirm
specif
psmadmab
plasmidderiv
antibodi
bind
recombin
human
psma
protein
fig
result
indic
psmadmab
plasmid
direct
product
antipsmaspecif
antibodi
vitro
abil
psmadmab
plasmid
direct
antibodi
product
vivo
evalu
immunedefici
nu
j
nude
immunecompet
mice
group
five
mice
receiv
singl
inject
psmadmab
plasmid
intramuscularli
quadricep
muscl
follow
ep
enhanc
deliveri
inject
mice
bled
variou
time
point
postinject
obtain
sera
evalu
elisa
quantit
human
igg
level
human
igg
becam
detect
sera
inject
mice
begin
day
postinject
peak
level
achiev
day
postinject
nude
fig
fig
mice
elev
human
igg
level
persist
nude
mice
beyond
day
level
mice
drop
baselin
valu
day
postinject
like
due
mous
antihuman
antibodi
respons
serum
collect
day
postinject
psmadmab
plasmidinject
nude
mice
evalu
elisa
fig
western
blot
fig
evalu
affin
specif
serum
igg
recombin
human
psma
assay
show
igg
day
sera
recogn
human
psma
irrelev
hiv
envelop
protein
high
affin
specif
suggest
igg
properli
fold
function
psmadmab
vivo
distribut
psmadmab
prostat
tissu
studi
mice
harvest
tissu
day
postplasmid
inject
perform
elisa
immunohistochemistri
igg
quantif
prostat
tissu
mice
administ
psmadmab
plasmid
exhibit
higher
level
human
igg
compar
prostat
tissu
empti
plasmidinject
mice
measur
elisa
tissu
homogen
fig
prostat
tissu
evalu
immunohistochemistri
stain
antihumanfc
express
strong
immunostain
signal
detect
cell
membran
within
prostat
psmadmab
plasmidinject
mice
control
fig
togeth
find
demonstr
psmadmab
plasmid
direct
product
robust
level
psmaspecif
human
igg
vivo
next
evalu
abil
psmadmab
mous
sera
bind
psma
tumor
cell
tissu
two
psmaexpress
prostat
cancer
cell
line
chosen
initi
studi
lncap
cell
deriv
human
prostat
adenocarcinoma
cell
transgen
adenocarcinoma
mous
prostat
tramp
cell
deriv
heterogen
tumor
grown
tramp
mous
model
cell
line
incub
sequenti
day
sera
psmadmab
plasmidinject
nude
mice
follow
fluoresc
label
antihuman
igg
secondari
antibodi
histogram
fig
mean
fluoresc
intens
mfi
fig
obtain
flow
cytometri
analysi
stain
cell
show
vivo
produc
psmadmab
bind
psmaposit
tumor
cell
line
stain
observ
psmaneg
cell
data
shown
addit
normal
cancer
prostat
cell
sever
studi
report
psma
express
wide
varieti
tumor
especi
tumor
neovasculatur
immunofluoresc
assay
use
evalu
abil
psmadmab
bind
psma
express
tissu
section
human
bladder
kidney
tumor
fig
result
show
psmadmab
abl
stain
cell
bladder
kidney
tumor
tissu
section
cell
normal
ovarian
tissu
confirm
previou
report
psma
express
tumor
furthermor
stain
show
psma
distribut
biolog
activ
psmadmab
next
evalu
use
antibodydepend
cellmedi
cytotox
adcc
mechan
action
assay
assay
involv
incub
psmaexpress
lncap
cell
effector
cell
h
presenc
differ
concentr
serum
psmadmab
plasmidinject
mice
effector
cell
jurkat
cell
stabli
express
highaffin
gene
firefli
luciferas
driven
nuclear
factor
activ
cell
nfat
respons
element
assay
readout
base
activ
gene
transcript
effector
cell
measur
firefli
luciferas
product
indic
fig
day
serum
psmadmab
plasmidinject
mice
mediat
adcc
effect
second
demonstr
biolog
activ
psmadmab
flow
cytometri
use
measur
apoptosi
necrosi
lncap
cell
cocultur
human
pbmc
presenc
sera
psmadmab
plasmidinject
mice
result
fig
show
statist
signific
increas
apoptosi
section
histogram
well
necrosi
section
histogram
lncap
cell
cocultur
human
pbmc
presenc
psmadmab
comparison
control
sera
combin
find
show
synthet
psmadmab
bind
fc
receptor
mediat
adcc
effect
tumor
cell
vivo
function
activ
psmadmab
assess
use
tumor
challeng
mous
model
assay
mice
subcutan
implant
tumor
cell
inject
week
later
either
psmadmab
plasmid
intramuscular
inject
enhanc
ep
mice
follow
day
regular
measur
tumor
size
made
mous
period
fig
tumor
mice
began
grow
day
postimplant
tumor
detect
psmadmabtr
mice
day
rapid
tumor
growth
note
control
group
psmadmabtr
group
exhibit
obviou
suppress
tumor
growth
due
antibodymedi
tumorprotect
immun
cours
observ
period
statist
signific
reduct
averag
tumor
volum
p
fig
signific
improv
surviv
p
mice
receiv
psmadmab
construct
compar
control
mice
fig
like
effect
might
enhanc
absenc
mous
antihuman
antibodi
respons
visual
inspect
fig
develop
group
reveal
tumor
psmadmab
group
impact
earli
remain
small
subderm
tumor
control
group
protrud
skin
becam
ulcer
antitumor
activ
mani
therapeut
antibodi
includ
adcc
antibodydepend
cellular
phagocytosi
adcp
depend
interact
iggfc
domain
fc
gamma
receptor
effector
cell
natur
killer
cell
express
high
level
therefor
also
examin
contribut
nk
cell
observ
effect
psmadmab
tumor
growth
previou
studi
report
human
igg
bind
activ
mous
induc
adccadcp
mous
nk
cell
mous
macrophag
group
mice
treat
either
control
igg
nk
celldeplet
igg
antibodi
implant
cell
one
week
later
mice
given
singl
inject
either
psmadmab
plasmid
subsequ
evalu
tumor
growth
day
rapid
onset
tumor
develop
acceler
tumor
growth
decreas
surviv
psmadmabimmun
nk
celldeplet
mice
p
fig
pretreat
control
igg
taken
togeth
data
demonstr
psmadmab
exert
profound
therapeut
effect
psmaexpress
tumor
vivo
support
possibl
applic
therapi
treatment
prostat
cancer
work
present
describ
construct
character
novel
dna
plasmidbas
deliveri
system
use
gener
protect
level
therapeut
mab
vivo
dna
plasmid
encod
v
h
v
l
segment
human
antipsma
mab
construct
demonstr
direct
express
fulllength
antigenspecif
igg
vitro
vivo
follow
electroporationenhanc
inject
muscl
mice
psma
highli
express
prostat
carcinoma
well
tumor
cell
consid
attract
target
antibodybas
therapi
due
express
surfac
cell
psmadmab
serum
mice
inject
psmadmab
plasmid
abl
bind
psma
surfac
lncap
prostat
tumor
cell
line
section
bladder
kidney
tumor
serum
antibodi
level
achiev
mice
inject
psmadmab
plasmid
day
postadministr
antibodi
remain
detect
sera
sever
week
importantli
psmadmab
retain
abil
recogn
psma
surfac
implant
tumor
cell
mediat
potent
antitumor
respons
vivo
due
least
part
interact
antibodi
rpsmamab
posit
control
use
luciferas
activ
measur
result
repres
data
two
independ
experi
b
flow
cytometr
analysi
effect
sera
collect
psmadmab
plasmidadminist
mice
lncap
cell
death
day
sera
incub
lncap
cell
absenc
presenc
human
pbmc
follow
wash
cell
stain
annexinv
propidium
iodid
pi
accord
manufactur
assay
specif
gate
fac
scan
panel
shown
variou
treatment
control
psmadmab
nontreat
cell
control
figur
illustr
repres
experi
two
perform
independ
nk
cell
mediat
adccadcp
tumor
cell
adcc
hypothes
major
mechan
mediat
antitumor
activ
mab
target
divers
malign
sever
mab
target
tumorspecif
antigen
immunomodulatori
molecul
use
develop
cancer
immunotherapi
regimen
impedi
widespread
use
one
primari
impedi
involv
cost
treatment
regimen
stem
labori
timeconsum
manufactur
purif
process
associ
make
proteinbas
drug
addit
multipl
infus
mab
often
requir
attain
maintain
efficaci
impos
cost
logist
constraint
patient
given
challeng
altern
approach
gener
deliv
mab
import
genebas
administr
approach
focus
deliv
gene
encod
protect
antibodi
antibodi
gener
vivo
sustain
manner
sever
group
develop
viral
vector
deliveri
mab
gene
shown
vector
use
drive
product
mab
vivo
howev
viral
vector
deliveri
gene
carri
challeng
high
develop
distribut
cost
well
potenti
neutral
gene
deliveri
inabl
redos
patient
immun
respons
gener
viral
vector
regard
dna
plasmidbas
deliveri
system
describ
possess
mani
uniqu
advantag
featur
use
specif
patient
treatment
primari
among
potenti
significantli
lower
cost
measur
weekli
mice
day
posttumor
administr
c
kaplanmei
curv
n
show
tumor
surviv
time
mice
psmadmab
group
repres
mice
tumor
psmadmab
plasmidinject
group
day
posttumor
administr
e
kaplanmei
curv
n
show
effect
nk
cell
deplet
psmadmabmedi
tumor
surviv
time
stem
lower
manufactur
cost
dna
plasmid
well
lower
distribut
cost
dna
stabl
simpl
produc
synthet
dna
vector
deliv
muscl
skin
aid
adapt
electropor
produc
high
durabl
level
vivo
transgen
express
without
integr
abund
clinic
data
speak
favor
safeti
profil
sinc
dna
plasmid
nonimmunogen
multipl
administr
differ
plasmid
contempl
deliveri
featur
particularli
import
serum
antibodi
level
decreas
anoth
antibodi
treatment
requir
first
report
describ
use
dna
plasmidbas
deliveri
system
direct
vivo
gener
therapeut
mab
target
relev
oncolog
target
psma
also
first
report
illustr
function
engag
host
nkimmun
clearanc
dnavector
mab
due
flexibl
platform
combin
dmab
plasmid
anticanc
treatment
immunotherapi
agent
import
consid
furtherr
studi
approach
neoplast
diseas
warrant
